公开(公告)号：US20210093719A1

公开(公告)日：2021-04-01

申请号：US17089928

申请日：2020-11-05

Applicant: Janssen Biotech, Inc.

Inventor： Michael Quigley ,  Andressa Smith

IPC: A61K39/395 ,  A61K31/4439 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  A61K45/06 ,  A61K31/501

Abstract: The present invention is directed to methods for treating cancer, preferably a solid tumor or hematological malignancy, including for example pancreatic cancer, lung cancer (including but not limited to non-small cell lung cancer (NSCLC)), prostate cancer, colorectal cancer, breast cancer, melanoma or non-Hodgkin's lymphoma, comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising, consisting or consisting essentially of (a) a small molecule CSF-1R inhibitor and (b) an agonistic antibody that binds CD40.

公开(公告)号：US10544229B2

公开(公告)日：2020-01-28

申请号：US15281670

申请日：2016-09-30

Applicant: Janssen Biotech, Inc.

Inventor： Johan Fransson ,  Paul Kim ,  Michael Quigley ,  Andressa Smith ,  Alexey Teplyakov ,  Hong Zhou

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  C07K16/42 ,  A61K47/68 ,  C07K16/46 ,  A61K39/00

Abstract: The present invention relates to agonistic antibodies specifically binding human CD40, polynucleotides encoding the antibodies or antigen-binding fragments, and methods of making and using the foregoing.

公开(公告)号：US10857230B2

公开(公告)日：2020-12-08

申请号：US15910392

申请日：2018-03-02

Applicant: Janssen Biotech, Inc.

Inventor： Michael Quigley ,  Andressa Smith

IPC: A61K39/00 ,  A61K39/395 ,  A61K31/4439 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  A61K45/06 ,  A61K31/501

Abstract: The present invention is directed to methods for treating cancer, preferably a solid tumor or hematological malignancy, including for example pancreatic cancer, lung cancer (including but not limited to non-small cell lung cancer (NSCLC)), prostate cancer, colorectal cancer, breast cancer, melanoma or non-Hodgkin's lymphoma, comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising, consisting or consisting essentially of (a) a small molecule CSF-1R inhibitor and (b) an agonistic antibody that binds CD40.

公开(公告)号：US20170088624A1

公开(公告)日：2017-03-30

申请号：US15281670

申请日：2016-09-30

Applicant: Janssen Biotech, Inc.

Inventor： Johan Fransson ,  Paul Kim ,  Michael Quigley ,  Andressa Smith ,  Alexey Teplyakov ,  Hong Zhou

IPC: C07K16/28 ,  A61K45/06 ,  C07K16/42 ,  A61K39/395

Abstract: The present invention relates to agonistic antibodies specifically binding human CD40, polynucleotides encoding the antibodies or antigen-binding fragments, and methods of making and using the foregoing.